Clinical Trial Update: v4 Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-491 [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 trial evaluating safety, tolerability, pharmacokinetics and pharmacodynamics of MYK-491 in heart failure with reduced ejection fraction an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dilated Cardiomyopathy
• Heart Failure with Reduced Ejection Fraction

Drugs mentioned

• MYK-491

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Heart Failure With Reduced Ejection Fraction, Dilated Cardiomyopathy | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-02-02